View ValuationPHC Holdings 将来の成長Future 基準チェック /36PHC Holdings利益と収益がそれぞれ年間31.8%と2.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に11% 31.8%なると予測されています。主要情報31.8%収益成長率31.84%EPS成長率Medical Equipment 収益成長16.1%収益成長率2.7%将来の株主資本利益率11.00%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 14PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026.お知らせ • Apr 03PHC Holdings Corporation to Report Fiscal Year 2026 Results on May 13, 2026PHC Holdings Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 13, 2026お知らせ • Jan 02Phc Holdings Corporation Announces Resignation of Koichiro Sato as Senior Executive Vice President, Representative Director and Chief Operating Officer, Effective January 2, 2026On December 31, 2025 (the “Execution Date”), Senseonics Holdings Inc. (the “Company”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“Senseonics Inc.” and together with the Company, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States (such assets, the “U.S. Purchased Assets”). Pursuant to the terms of the Master Asset Purchase Agreement, the Purchaser Parties agreed to assume certain liabilities and obligations associated with the U.S. Purchased Assets (the “U.S. Assumed Liabilities” and together with the U.S. Purchased Assets, the “U.S. Asset Purchase”), including, but not limited to, certain liabilities under the contracts transferred to the Purchaser Parties under the Master Asset Purchase Agreement, liabilities arising out of the use or ownership of the transferred assets after the closing, and liabilities and obligations arising from certain employees whose employment is transferred to Senseonics Inc. pursuant to new employment letter agreements with Senseonics Inc. The U.S. Asset Purchase closed on January 1, 2026 (the “U.S. Closing”). On the Execution Date, in connection with the transactions described in Item 1.01 of this report, Koichiro Sato, Senior Executive Vice President, Representative Director and Chief Operating Officer of PHC Holdings Corporation, the parent company of the Seller, notified the board of directors (the “Board”) of the Company of his resignation from the Board effective immediately. Mr. Sato’s resignation is not due to any disagreements with the Company, management or Board on any matter relating to the Company’s operations, policies, or practices.お知らせ • Dec 02PHC Holdings Corporation to Report Q3, 2026 Results on Feb 12, 2026PHC Holdings Corporation announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Nov 12+ 1 more updatePHC Holdings Corporation Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2026, Payable on December 18, 2025PHC Holdings Corporation announced dividend for the second quarter end of the fiscal year ending March 31, 2026. For the period, the company announced dividend of JPY 21.00 per share against JPY 21.00 per share a year ago. Scheduled date to commence dividend payments: December 18, 2025.お知らせ • Sep 04PHC Holdings Corporation to Report Q2, 2026 Results on Nov 12, 2025PHC Holdings Corporation announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • May 31PHC Holdings Corporation to Report Q1, 2026 Results on Aug 07, 2025PHC Holdings Corporation announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 13PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025.お知らせ • Mar 07PHC Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025PHC Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Dec 06PHC Holdings Corporation to Report Q3, 2025 Results on Feb 12, 2025PHC Holdings Corporation announced that they will report Q3, 2025 results on Feb 12, 2025お知らせ • Sep 04+ 1 more updatePHC Holdings Corporation to Report Q2, 2025 Results on Nov 13, 2024PHC Holdings Corporation announced that they will report Q2, 2025 results on Nov 13, 2024お知らせ • Aug 30Phc Unveils Prototype of Licellgrow, New Cell Expansion System to Support Development of Cell and Gene Therapy Products Manufacturing ProcessPHC Corporation Biomedical Division will showcase a prototype of its new cell expansion system LiCellGrow at the ISCT (International Society for Cell & Gene Therapy) Europe 2024 Regional Meeting held in Gothenburg, Sweden on September 4-6. LiCellGrow, currently under development, is designed to allow pharmaceutical companies to visualize continuous metabolic changes in cells in real-time and adjust the cell culture automatically to optimize conditions for cell growth. The system seeks to expand availability of cell and gene therapy products by accelerating the manufacturing of specific cells needed for these therapies. CGT, in which a patient’s cells are removed, modified, and reintroduced to the body to fight disease, has emerged as a promising therapeutic field for difficult-to-treat conditions such as cancers and hematologic disorders. Since the patient’s own cells are used as raw materials, it is essential to maintain stable cell quality when producing new cells, to counteract natural variations in cell characteristics and ensure consistency throughout the therapy manufacturing process. The current method of evaluating cell quality by sampling the final product may lower both manufacturing efficiency and yield, increasing production cost. LiCellGrow seeks to enable more efficient and stable manufacture of high-quality CGT products by enabling researchers to monitor and control the cell culture environment in real time, optimizing cell quality while minimizing interruption to the therapy manufacturing process. The system under development uses proprietary In-Line monitoring technology, which continuously measures cell metabolites in the culture medium without the need for repeated sampling by immersing sensors in the medium at all times. LiCellGrow then continuously and accurately measures concentrations of two critical indicators of cell metabolism, glucose and lactate, to offer a visualization of actual changes in the culture environment and cell status. Based on real-time measurement data, the system then automatically exchanges the culture medium to maintain the culture environment in an optimal state. This technology is designed to improve and homogenize cell quality while increasing cell culture efficiency and reducing costs through loss reduction. The system will also feature easy-to-install single-use culture bags with In-Line sensors, enabling closed-system cell culturing to maintain a sterile environment, and can be installed in existing CO2 incubators, enabling researchers to conduct studies using their preferred equipment. LiCellGrow is an example of synergy between the Biomedical Division and IVD Division of PHC Corporation. The In-Line monitoring technology featured in this cell expansion system is newly developed proprietary technology building on the core technology of blood glucose sensor, the main product developed by IVD. By combining this sensor technology from IVD with advanced cell culture environment control technology from the Biomedical Division, PHC seeks to offer researchers and pharmaceutical companies greater value. The Biomedical Division plans to launch LiCellGrow to support the development of manufacturing processes for CGT products globally in the short term, and aims to accelerate development of this system to ultimately support commercialized production of CGT products. LiCellGrow builds on the Biomedical Division’s 20-year history of pioneering solutions in the field of cell therapy, including the Cell Processing Center in 2000 and the Cell Processing Isolator in 2007. Moving forward, they will continue to accelerate the creation of innovative solutions addressing QCD challenges in the therapeutic manufacturing process for early adoption of CGT, aiming to contribute to advancing modalities.お知らせ • Jun 28PHC Holdings Corporation to Report Q1, 2025 Results on Aug 08, 2024PHC Holdings Corporation announced that they will report Q1, 2025 results on Aug 08, 2024お知らせ • May 12PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024.お知らせ • Mar 09PHC Holdings Corporation to Report Fiscal Year 2024 Results on May 10, 2024PHC Holdings Corporation announced that they will report fiscal year 2024 results on May 10, 2024お知らせ • Feb 13+ 1 more updatePHC Holdings Co., Ltd. Announces Management ChangesPHC Holdings Co. Ltd. has decided that Kyoko Deguchi will be appointed as the company's representative director and president on April 1, 2024. Masatsugu Miyazaki will step down from his duties as Representative director and president on March 31, and will continue to serve as a director until the general meeting of shareholders to be held in June. Mr. Deguchi, who is currently an independent director of the Company, has over 20 years of experience in the healthcare and chemical industries, and has previously served as head of the Japanese subsidiary of various global healthcare companies, including Janssen Pharmaceuticals, Stryker, and AbbVie. He has held senior positions in finance, marketing, etc. Currently, he is involved in management as the vice director of rehabilitation orthopedics, and has experience as an outside director at multiple listed and unlisted companies, including T-Gaia Co. Ltd. and Heartseed Co. Ltd.お知らせ • Dec 09PHC Holdings Corporation to Report Q3, 2024 Results on Feb 09, 2024PHC Holdings Corporation announced that they will report Q3, 2024 results on Feb 09, 2024お知らせ • Aug 30PHC Holdings Corporation to Report Q2, 2024 Results on Nov 10, 2023PHC Holdings Corporation announced that they will report Q2, 2024 results on Nov 10, 2023お知らせ • Jul 11Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on July 10, 2023.お知らせ • Jun 23Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.お知らせ • Jun 15PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd.PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.PHC Holdings Corporation (TSE:6523) completed the acquisition of remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.お知らせ • May 28PHC Holdings Corporation to Report Q1, 2024 Results on Aug 10, 2023PHC Holdings Corporation announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • May 13PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023.業績と収益の成長予測OTCPK:PHCC.F - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2029393,40022,30025,60052,30013/31/2028374,34817,11927,25043,52663/31/2027366,43914,57827,89747,60053/31/2026364,40349233,36542,458N/A12/31/2025363,9343,54132,03141,491N/A9/30/2025361,1055,82630,16740,260N/A6/30/2025360,26211,31731,86942,114N/A3/31/2025361,59310,48530,33141,941N/A12/31/2024364,1275,90028,16440,440N/A9/30/2024360,944-6,33618,78832,394N/A6/30/2024357,762-12,86623,87938,292N/A3/31/2024353,900-12,89326,67441,304N/A12/31/2023348,015-17,77928,31243,061N/A9/30/2023352,669-6,87425,83838,598N/A6/30/2023356,25768415,72127,684N/A3/31/2023356,434-3,2229,86021,376N/A12/31/2022353,186-23,57011,37721,882N/A9/30/2022344,985-22,25725,52636,254N/A6/30/2022341,045-25,950N/AN/AN/A3/31/2022340,452-8,46039,31751,053N/A3/31/2021306,07116,906N/AN/AN/A3/31/2020272,6375,276N/AN/AN/A3/31/2019186,54615,453N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHCC.Fの予測収益成長率 (年間31.8% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: PHCC.Fの収益 ( 31.8% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: PHCC.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: PHCC.Fの収益 ( 2.7% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: PHCC.Fの収益 ( 2.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHCC.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 11 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:59終値2026/03/30 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PHC Holdings Corporation 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Kei TakeuchiBofA Global ResearchHidemaru YamaguchiCitigroup IncAkinori UedaGoldman Sachs7 その他のアナリストを表示
お知らせ • May 14PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026.
お知らせ • Apr 03PHC Holdings Corporation to Report Fiscal Year 2026 Results on May 13, 2026PHC Holdings Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 13, 2026
お知らせ • Jan 02Phc Holdings Corporation Announces Resignation of Koichiro Sato as Senior Executive Vice President, Representative Director and Chief Operating Officer, Effective January 2, 2026On December 31, 2025 (the “Execution Date”), Senseonics Holdings Inc. (the “Company”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“Senseonics Inc.” and together with the Company, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States (such assets, the “U.S. Purchased Assets”). Pursuant to the terms of the Master Asset Purchase Agreement, the Purchaser Parties agreed to assume certain liabilities and obligations associated with the U.S. Purchased Assets (the “U.S. Assumed Liabilities” and together with the U.S. Purchased Assets, the “U.S. Asset Purchase”), including, but not limited to, certain liabilities under the contracts transferred to the Purchaser Parties under the Master Asset Purchase Agreement, liabilities arising out of the use or ownership of the transferred assets after the closing, and liabilities and obligations arising from certain employees whose employment is transferred to Senseonics Inc. pursuant to new employment letter agreements with Senseonics Inc. The U.S. Asset Purchase closed on January 1, 2026 (the “U.S. Closing”). On the Execution Date, in connection with the transactions described in Item 1.01 of this report, Koichiro Sato, Senior Executive Vice President, Representative Director and Chief Operating Officer of PHC Holdings Corporation, the parent company of the Seller, notified the board of directors (the “Board”) of the Company of his resignation from the Board effective immediately. Mr. Sato’s resignation is not due to any disagreements with the Company, management or Board on any matter relating to the Company’s operations, policies, or practices.
お知らせ • Dec 02PHC Holdings Corporation to Report Q3, 2026 Results on Feb 12, 2026PHC Holdings Corporation announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Nov 12+ 1 more updatePHC Holdings Corporation Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2026, Payable on December 18, 2025PHC Holdings Corporation announced dividend for the second quarter end of the fiscal year ending March 31, 2026. For the period, the company announced dividend of JPY 21.00 per share against JPY 21.00 per share a year ago. Scheduled date to commence dividend payments: December 18, 2025.
お知らせ • Sep 04PHC Holdings Corporation to Report Q2, 2026 Results on Nov 12, 2025PHC Holdings Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • May 31PHC Holdings Corporation to Report Q1, 2026 Results on Aug 07, 2025PHC Holdings Corporation announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 13PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025.
お知らせ • Mar 07PHC Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025PHC Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Dec 06PHC Holdings Corporation to Report Q3, 2025 Results on Feb 12, 2025PHC Holdings Corporation announced that they will report Q3, 2025 results on Feb 12, 2025
お知らせ • Sep 04+ 1 more updatePHC Holdings Corporation to Report Q2, 2025 Results on Nov 13, 2024PHC Holdings Corporation announced that they will report Q2, 2025 results on Nov 13, 2024
お知らせ • Aug 30Phc Unveils Prototype of Licellgrow, New Cell Expansion System to Support Development of Cell and Gene Therapy Products Manufacturing ProcessPHC Corporation Biomedical Division will showcase a prototype of its new cell expansion system LiCellGrow at the ISCT (International Society for Cell & Gene Therapy) Europe 2024 Regional Meeting held in Gothenburg, Sweden on September 4-6. LiCellGrow, currently under development, is designed to allow pharmaceutical companies to visualize continuous metabolic changes in cells in real-time and adjust the cell culture automatically to optimize conditions for cell growth. The system seeks to expand availability of cell and gene therapy products by accelerating the manufacturing of specific cells needed for these therapies. CGT, in which a patient’s cells are removed, modified, and reintroduced to the body to fight disease, has emerged as a promising therapeutic field for difficult-to-treat conditions such as cancers and hematologic disorders. Since the patient’s own cells are used as raw materials, it is essential to maintain stable cell quality when producing new cells, to counteract natural variations in cell characteristics and ensure consistency throughout the therapy manufacturing process. The current method of evaluating cell quality by sampling the final product may lower both manufacturing efficiency and yield, increasing production cost. LiCellGrow seeks to enable more efficient and stable manufacture of high-quality CGT products by enabling researchers to monitor and control the cell culture environment in real time, optimizing cell quality while minimizing interruption to the therapy manufacturing process. The system under development uses proprietary In-Line monitoring technology, which continuously measures cell metabolites in the culture medium without the need for repeated sampling by immersing sensors in the medium at all times. LiCellGrow then continuously and accurately measures concentrations of two critical indicators of cell metabolism, glucose and lactate, to offer a visualization of actual changes in the culture environment and cell status. Based on real-time measurement data, the system then automatically exchanges the culture medium to maintain the culture environment in an optimal state. This technology is designed to improve and homogenize cell quality while increasing cell culture efficiency and reducing costs through loss reduction. The system will also feature easy-to-install single-use culture bags with In-Line sensors, enabling closed-system cell culturing to maintain a sterile environment, and can be installed in existing CO2 incubators, enabling researchers to conduct studies using their preferred equipment. LiCellGrow is an example of synergy between the Biomedical Division and IVD Division of PHC Corporation. The In-Line monitoring technology featured in this cell expansion system is newly developed proprietary technology building on the core technology of blood glucose sensor, the main product developed by IVD. By combining this sensor technology from IVD with advanced cell culture environment control technology from the Biomedical Division, PHC seeks to offer researchers and pharmaceutical companies greater value. The Biomedical Division plans to launch LiCellGrow to support the development of manufacturing processes for CGT products globally in the short term, and aims to accelerate development of this system to ultimately support commercialized production of CGT products. LiCellGrow builds on the Biomedical Division’s 20-year history of pioneering solutions in the field of cell therapy, including the Cell Processing Center in 2000 and the Cell Processing Isolator in 2007. Moving forward, they will continue to accelerate the creation of innovative solutions addressing QCD challenges in the therapeutic manufacturing process for early adoption of CGT, aiming to contribute to advancing modalities.
お知らせ • Jun 28PHC Holdings Corporation to Report Q1, 2025 Results on Aug 08, 2024PHC Holdings Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
お知らせ • May 12PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024.
お知らせ • Mar 09PHC Holdings Corporation to Report Fiscal Year 2024 Results on May 10, 2024PHC Holdings Corporation announced that they will report fiscal year 2024 results on May 10, 2024
お知らせ • Feb 13+ 1 more updatePHC Holdings Co., Ltd. Announces Management ChangesPHC Holdings Co. Ltd. has decided that Kyoko Deguchi will be appointed as the company's representative director and president on April 1, 2024. Masatsugu Miyazaki will step down from his duties as Representative director and president on March 31, and will continue to serve as a director until the general meeting of shareholders to be held in June. Mr. Deguchi, who is currently an independent director of the Company, has over 20 years of experience in the healthcare and chemical industries, and has previously served as head of the Japanese subsidiary of various global healthcare companies, including Janssen Pharmaceuticals, Stryker, and AbbVie. He has held senior positions in finance, marketing, etc. Currently, he is involved in management as the vice director of rehabilitation orthopedics, and has experience as an outside director at multiple listed and unlisted companies, including T-Gaia Co. Ltd. and Heartseed Co. Ltd.
お知らせ • Dec 09PHC Holdings Corporation to Report Q3, 2024 Results on Feb 09, 2024PHC Holdings Corporation announced that they will report Q3, 2024 results on Feb 09, 2024
お知らせ • Aug 30PHC Holdings Corporation to Report Q2, 2024 Results on Nov 10, 2023PHC Holdings Corporation announced that they will report Q2, 2024 results on Nov 10, 2023
お知らせ • Jul 11Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on July 10, 2023.
お知らせ • Jun 23Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.
お知らせ • Jun 15PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd.PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.PHC Holdings Corporation (TSE:6523) completed the acquisition of remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.
お知らせ • May 28PHC Holdings Corporation to Report Q1, 2024 Results on Aug 10, 2023PHC Holdings Corporation announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • May 13PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023.